Radiation Therapy Without Hormone Therapy for Women Age 70 or Above with Low-Risk Early Breast Cancer: A Microsimulation.
Aged
Aged, 80 and over
Anastrozole
/ economics
Antineoplastic Agents, Hormonal
/ economics
Aromatase Inhibitors
/ economics
Breast Neoplasms
/ chemistry
Clinical Trials as Topic
Cost-Benefit Analysis
Dose Fractionation, Radiation
Female
Humans
Markov Chains
Mastectomy, Segmental
Meta-Analysis as Topic
Neoplasm Recurrence, Local
/ prevention & control
Probability
Prospective Studies
Quality-Adjusted Life Years
Radiotherapy
/ economics
Radiotherapy, Adjuvant
Receptors, Estrogen
Relative Biological Effectiveness
Risk
Salvage Therapy
/ methods
Journal
International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616
Informations de publication
Date de publication:
01 10 2019
01 10 2019
Historique:
received:
11
04
2019
revised:
04
06
2019
accepted:
08
06
2019
pubmed:
19
6
2019
medline:
28
1
2020
entrez:
19
6
2019
Statut:
ppublish
Résumé
Hormone therapy without radiation therapy is considered appropriate for women age 70 or above with low-risk, hormone-positive breast cancer after partial mastectomy. However, some patients may prefer radiation without hormone therapy, for which there is minimal modern data. We modeled the comparative efficacy of aromatase inhibition alone without radiation versus radiation alone without hormone therapy. We constructed a patient-level Markov model and compared 5 years of anastrozole to a 15-fraction course of radiation without boost or anastrozole. The relative effectiveness between treatments was based on the National Surgical Adjuvant Breast and Bowel Project B-21 trial, which was further adjusted such that the endocrine-alone arm matched the Cancer and Leukemia Group B 9343 and PRIME II trials. Common or severe side effects were considered. Eight survival metrics were assessed and validated against clinical trial data. The cost-efficacy of each strategy was considered using the quality-adjusted life year and incremental cost-effectiveness ratio (ICER). The model's predicted outcomes matched those demonstrated by modern trials. Aromatase inhibitors were superior in preventing contralateral cancers, with a small impact on the risk of distant metastatic disease. Radiation was superior in preventing ipsilateral breast tumor recurrence with a small impact on regional failure. No clinically significant differences were seen in the other 4 oncologic endpoints. Differences in quality-adjusted life years were small, but radiation therapy was $3809 more expensive over the average lifetime. The ICER suggested anastrozole was cost-effective in 62% of probabilistic simulations. However, the ICER was unstable owing to a denominator that approached zero. Women age 70 or above with low-risk early breast cancer who are reluctant or unable to pursue adjuvant aromatase inhibition can safely pursue adjuvant radiation alone with limited differences in outcome and a modest increase in costs.
Identifiants
pubmed: 31212043
pii: S0360-3016(19)30849-1
doi: 10.1016/j.ijrobp.2019.06.014
pii:
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Aromatase Inhibitors
0
Receptors, Estrogen
0
Anastrozole
2Z07MYW1AZ
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
296-306Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.